Antipsychotic-evoked dopamine supersensitivity

@article{Servonnet2020AntipsychoticevokedDS,
  title={Antipsychotic-evoked dopamine supersensitivity},
  author={Alice Servonnet and A. Samaha},
  journal={Neuropharmacology},
  year={2020},
  volume={163}
}
All antipsychotic medications attenuate the symptoms of psychosis by interacting with dopamine D2 receptors and reducing dopamine-mediated neurotransmission. However, long-term antipsychotic treatment can produce neuroadaptations that are thought to lead to dopamine supersensitivity. In patients with schizophrenia, this dopamine supersensitivity could compromise treatment efficacy, promote relapse to psychosis and trigger movement disorders. Such effects have been seen in patients treated with… Expand
Continuous versus extended antipsychotic dosing in schizophrenia: Less is more
TLDR
It is proposed that regular, but extended dosing should be considered in the long-term treatment of people with schizophrenia, because the available evidence suggests it can be just as effective as continuous treatment, while decreasing overall drug exposure and potentially reducing harmful side effects. Expand
Dopamine D2 up-regulation in psychosis patients after antipsychotic drug treatment.
TLDR
Further research is needed to investigate whether antipsychotic medication causes neuroadaptations leading to a dopamine supersensitive state in humans, how long such hypersensitive states may last and what differences exist between high and low D2 affinity antipsychotics. Expand
Rationale and neurobiological effects of treatment with antipsychotics in patients with chronic schizophrenia considering dopamine supersensitivity
TLDR
The characteristics of long-acting injectable antipsychotics, dopamine partial agonists, and clozapine in relation to dopamine supersensitivity from the viewpoints of receptor profiles and pharmacokinetics and the biological influence of antipsychotic treatment on the human brain are discussed. Expand
Pharmacotherapy of schizophrenia: Mechanisms of antipsychotic accumulation, therapeutic action and failure
TLDR
Manipulating the accumulation properties of APDs, changes in the administration regimen and doses, or co-administration with dopamine transporter inhibitors may be considered to yield benefits in the development of new effective strategies in the treatment of schizophrenia. Expand
Individualizing tapering antipsychotic schemes considering D2 blockade dynamics
To the editor, Tapering antipsychotic dose in schizophrenia treatment is good clinical practice, as current guidelines suggest using a minimum effective dose to reduce the burden related to adverseExpand
Effects of dopamine receptor antagonism and amphetamine-induced psychomotor sensitization on sign- and goal-tracking after extended training
TLDR
The effects of dopamine D1-like and D2-like receptor antagonism on the expression of sign-tracking and goal-tracking conditioned responses following extended Pavlovian conditioned approach (PCA) training were tested and psychomotor sensitization to amphetamine did not impact incentive salience attribution. Expand
Effects of dopamine receptor antagonism and amphetamine-induced psychomotor sensitization on sign- and goal-tracking after extended training
TLDR
Psychomotor sensitization to amphetamine did not impact incentive salience attribution and more selective manipulations of the dopamine system may be needed, but following extended PCA training, dopamine D2-like receptor activity is required for the expression of goal-tracking but not sign-tracking. Expand
Towards a framework to develop neuroimaging biomarkers of relapse in schizophrenia
TLDR
There is great need to identify biomarkers of relapse in schizophrenia to stratify treatment according to the risk and develop therapeutics targeting its pathophysiology, and it is necessary to create a framework by identifying the challenges to this type of study as well as potential areas for biomarker identification and development. Expand
Влияние клинических и терапевтических показателей на выраженность нейрокогнитивного дефицита у пациентов с шизофренией
TLDR
The severity of positive symptoms of schizophrenia was lower in patients with mild neurocognitive deficits, and the most pronounced neuroc cognitive deficits are observed in patients receiving AAD. Expand
Antipsychotics Circa 2020: What are we thinking?
...
1
2
...

References

SHOWING 1-10 OF 181 REFERENCES
Antipsychotic-Induced Dopamine Supersensitivity Psychosis: Pharmacology, Criteria, and Therapy
TLDR
Criteria for SP is proposed, which describe psychotic symptoms and co-occurring movement disorders more precisely, and 3 antipsychotic withdrawal syndromes are described, similar to those seen with other CNS drugs, and approaches to treat, potentially prevent, or temporarily manage SP are proposed. Expand
“Breakthrough” Dopamine Supersensitivity during Ongoing Antipsychotic Treatment Leads to Treatment Failure over Time
TLDR
It is shown that during ongoing treatment with clinically relevant doses, haloperidol and olanzapine progressively lose their efficacy in suppressing amphetamine-induced locomotion and conditioned avoidance responding and is linked to an increase in D2 receptor number and sensitivity. Expand
Antipsychotic treatment leading to dopamine supersensitivity persistently alters nucleus accumbens function
TLDR
Antipsychotic-induced dopamine supersensitivity persistently disrupts NAc function, such that some behaviors that normally depend upon NAc dopamine no longer do so, and has implications for understanding dysfunctions in dopamine-mediated behaviors in patients undergoing chronic antipsychotic treatment. Expand
Can antipsychotic treatment contribute to drug addiction in schizophrenia?
  • A. Samaha
  • Psychology, Medicine
  • Progress in Neuro-Psychopharmacology and Biological Psychiatry
  • 2014
TLDR
By inducing forms of neural plasticity that facilitate the ability of drugs and reward cues to gain control over behaviour, some currently used treatment strategies with typical antipsychotics might contribute to compulsive drug seeking and drug taking behaviours in vulnerable schizophrenia patients. Expand
5-HT2 receptors modulate the expression of antipsychotic-induced dopamine supersensitivity
TLDR
It is suggested that blockade of 5-HT2A receptors might overcome some of the behavioural manifestations of antipsychotic-induced dopamine supersensitivity, which is potentially linked to changes in 5- HT2A receptor density in the prefrontal cortex and the striatum. Expand
Dynamic regulation of dopamine and serotonin responses to salient stimuli during chronic haloperidol treatment.
TLDR
In-vivo voltammetry showed that nucleus accumbens dopamine adaptations and their reversal were mediated by changes in extracellular dopamine release, which may be a functional substrate of antipsychotic action and failure respectively. Expand
A dopaminergic mechanism of antipsychotic drug efficacy, failure, and failure reversal: the role of the dopamine transporter
TLDR
It is reported that antipsychotic efficacy in rat models declines in concert with extracellular striatal dopamine levels rather than insufficient dopamine D2 receptor occupancy, supporting the hypothesis that the dopamine transporter is a main target of antippsychotic drugs and predicting that dopamine transporter blockers may be an adjunct treatment to reverse antipsychotics treatment failure. Expand
Optimal Extent of Dopamine D2 Receptor Occupancy by Antipsychotics for Treatment of Dopamine Supersensitivity Psychosis and Late-Onset Psychosis
TLDR
It is hypothesized that there is an optimal range in the number of D2 receptors available for dopamine binding to elicit adequate neurotransmission in the treatment of patients with schizophrenia and the results indicated that the reduction of the plasma antipsychotic level is greater during a given time period in patients with higher D2 density. Expand
Increased dopamine D2 receptor binding after long-term treatment with antipsychotics in humans: a clinical PET study
TLDR
It is demonstrated for the first time, using in vivo neuroreceptor imaging, that dopamine D2 receptor binding is increased after long-term treatment with antipsychotics in humans. Expand
Prior haloperidol, but not olanzapine, exposure augments the pursuit of reward cues: implications for substance abuse in schizophrenia.
TLDR
It is suggested that HAL, but not an atypical like OLZ, modifies reward circuitry in ways that increase responsiveness to reward cues, which could help schizophrenic patients at risk for drug abuse or addiction. Expand
...
1
2
3
4
5
...